How many chronic myeloid leukemia patients who started a frontline second‐generation tyrosine kinase inhibitor have to switch to a second‐line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA)

The frequency of patients who switch to a second‐line therapy from a frontline second‐generation (2gen) tyrosine kinase inhibitor (TKI) such as dasatinib and nilotinib, is still substantially unknown. We retrospectively investigated a large series of chronic phase chronic myeloid leukemia (CP‐CML) p...

Descripción completa

Detalles Bibliográficos
Autores principales: Breccia, Massimo, Olimpieri, Pier Paolo, Olimpieri, Odoardo, Pane, Fabrizio, Iurlo, Alessandra, Foggi, Paolo, Cirilli, Alessia, Colatrella, Antonietta, Cuomo, Marcello, Gozzo, Lucia, Summa, Valentina, Corradini, Paolo, Russo, Pierluigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300412/
https://www.ncbi.nlm.nih.gov/pubmed/32319737
http://dx.doi.org/10.1002/cam4.3071

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300412/
https://www.ncbi.nlm.nih.gov/pubmed/32319737
http://dx.doi.org/10.1002/cam4.3071

Ejemplares similares